About: Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 +/- 3.9 months for 'low' expressed and 7.5 +/- 5.6 months for 'high' expressed group, p < 0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 +/- 3.6 months for 'low' and 8.4 +/- 2.7 months for 'high' expressed group, p < 0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 +/- 2.8 months for 'low' and 9.8 +/- 1.1 months for 'high' expressed group, p < 0.0001). The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 +/- 3.9 months for 'low' expressed and 7.5 +/- 5.6 months for 'high' expressed group, p < 0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 +/- 3.6 months for 'low' and 8.4 +/- 2.7 months for 'high' expressed group, p < 0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 +/- 2.8 months for 'low' and 9.8 +/- 1.1 months for 'high' expressed group, p < 0.0001). (en)
Title	Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia (en)
skos:prefLabel	Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia (en)
skos:notation	RIV/00216224:14110/13:00065643!RIV14-MZ0-14110___
http://linked.open...avai/riv/aktivita	I P V
http://linked.open...avai/riv/aktivity	I, P(GAP304/10/1395), P(NT11154), P(NT11159), P(NT12130), P(NT13190), V
http://linked.open...iv/cisloPeriodika	4
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Kryukov, Fedor Ševčíková, Sabina Dementyeva, Elena Vladimirovna Kuglík, Petr Petrík, Jakub Brožová, Lucie Jarkovský, Jiří Hájek, Roman Němec, Pavel Kubiczková, Lenka
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	64478
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/13:00065643
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Multiple myeloma; Plasma cell leukemia; Cell cycle genes; Overall survival; Time-to-progression (en)
http://linked.open.../riv/klicoveSlovo	Cell cycle genes Plasma cell leukemia Time-to-progression Overall survival Multiple myeloma
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[892321B9A8FF]
http://linked.open...i/riv/nazevZdroje	Genomics
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	10 (xsd:int)
http://linked.open...cetTvurcuVysledku	12 (xsd:int)
http://linked.open...vavai/riv/projekt	The role of B cell lineage mitotic disruptions in multiple myeloma Molecular typing of syphilis-causing strains in the Czech Republic and detection of mutations leading to macrolide resistance Analysis of Clonal Plasma Cells Progenitors in Monoclonal Gammopathies Molecular signature of centrosome abnormalities and their clinical impact for patients with multiple myeloma Complex analysis of importance and pathogenesis of extramedullary relapse in patients with multiple myeloma
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	102
http://linked.open...iv/tvurceVysledku	Dementyeva, Elena Vladimirovna Hájek, Roman Jarkovský, Jiří Kuglík, Petr Kryukov, Fedor Ševčíková, Sabina Němec, Pavel Brožová, Lucie Kubiczková, Lenka Minarik, Jiří Petrík, Jakub Stefanikova, Zdena
http://linked.open...ain/vavai/riv/wos	000326425300009
issn	0888-7543
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.ygeno.2013.06.007
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software